SIMULTANEOUS EXPRESSION OF T-CELL ACTIVATING ANTIGENS IN RENAL CELL CARCINOMA: IMPLICATIONS FOR SPECIFIC IMMUNOTHERAPY

Abstract

We noted that T-cell activating tumor associated antigens are frequently expressed in patients with RCC. Based on HLA expression analysis in a white population at least 30% of patients with RCC are eligible for monovalent specific immunotherapy and 41% are eligible for polyvalent specific immunotherapy. These data are a rational basis for future prospective vaccination trials in patients with RCC.